

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An anti-SARS virus monoclonal antibody against nucleoprotein of a corona virus which causes severe acute respiratory syndrome (SARS), ~~or an antigen-binding fragment thereof~~ produced by a hybridoma prepared by using as an immunogen the nucleoprotein of said coronavirus, said nucleoprotein being expressed by a vector in which a nucleotide sequence shown in SEQ ID NO: 1 is incorporated, or an antigen binding fragment thereof.

2. (Original) The anti-SARS virus monoclonal antibody or the antigen-binding fragment thereof according to claim 1, which is a monoclonal antibody.

3. (Canceled)

4. (Currently Amended) The anti-SARS virus monoclonal antibody or the antigen-binding fragment thereof according to claim ~~[[3]]~~ 1, which monoclonal antibody has binding specificity of the monoclonal antibody produced by hybridoma rSN-18 having an Accession No. FERM BP-10143, hybridoma rSN-122 having an Accession No. FERM BP-10144, hybridoma rSN-150 having an Accession No. FERM BP-10145, hybridoma rSN-21-2 having an Accession No. FERM BP-10146 or hybridoma rSN-29 having an Accession No. FERM BP-10147.

5. (Withdrawn) The anti-SARS virus monoclonal antibody or the antigen-binding fragment thereof according to claim 1, which monoclonal antibody is produced by a hybridoma prepared by using as an immunogen the amino acid sequence shown in SEQ ID NO: 3.

6. (Previously Presented) A hybridoma producing said monoclonal antibody according to claim 1, which hybridoma is obtained by fusing an anti-SARS virus monoclonal antibody-producing cell and a tumor cell.

7. (Currently Amended) Hybridoma rSN-18 having an Accession No. FERM BP-10143, hybridoma rSN-122 having an Accession No. FERM BP-10144, hybridoma rSN-150 having an Accession No. FERM BP-10145, hybridoma rSN-21-2 having an Accession No. FERM BP-10146 or hybridoma rSN-29 having an Accession No. FERM BP-10147, which hybridomas produce said monoclonal antibody ~~or the antigen-binding fragment thereof~~ recited in claim 1.

8. (Previously Presented) An reagent for immunoassay of SARS-causing coronavirus, comprising said monoclonal antibody or an antigen binding fragment thereof according to claim 1 as at least one of immobilized antibody and labeled antibody.

9. (Withdrawn) An immunoassay device comprising a detection zone having an anti-SARS virus antibody immobilized on a matrix through which liquid can be transported; and a labeled reagent zone on which a labeled anti-SARS antibody is spotted in such a manner that said labeled anti-SARS antibody is mobile; at least one of said antibody immobilized on said

detection zone and said labeled anti-SARS virus antibody being said monoclonal antibody or the antigen-binding fragment thereof according to claim 1.

10. (Withdrawn) The immunoassay device according to claim 9, wherein said label is an enzyme and wherein said immunoassay device has a substrate at a region upstream of said labeled reagent zone in said matrix, said substrate reacting said enzyme.

11. (Previously Presented) An immunoassay of SARS virus, comprising detecting said SARS virus in a test sample by an immunoassay utilizing antigen-antibody reaction between said anti-SARS virus monoclonal antibody or the antigen-binding fragment thereof according to claim 1 and said SARS virus in said test sample.

12. (New) The anti-SARS virus monoclonal antibody or the antigen-binding fragment thereof according to claim 4, which is a monoclonal antibody.